Exact Mass: 433.1923
Exact Mass Matches: 433.1923
Found 327 metabolites which its exact mass value is equals to given mass value 433.1923
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
8-[[(1R)-1-(3,4-Dimethoxyphenyl)-2-hydroxyethyl]amino]-7-(2-methoxyethyl)-1,3-dimethylpurine-2,6-dione
Arg-gly-asp-ser
Belotecan
Brexpiprazole
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine D2L receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α1B (Ki=0.17 nM) and α2C receptors (Ki=0.59 nM)[1][2].
8-((4-Amino-1-methylbutyl)amino)-6-methoxy-4-methyl-5-(3-trifluoromethylphenoxy)quinoline
L-Alanine, 3-(((3-(4-(aminoiminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, (R)-
(3,5-Isomer,6-oxo,N-Me-Gerambullin|Methylisogerambullone|methylisogerammbullone|MIGB
6-Oxo,N-Me-Gerambullin|Methylgerambullone|methylgerammbullone
(-)-8alpha-(4-methoxybenzyl)-2-methoxyberbin-3,10,11-triol|(-)-8alpha-<4-methoxybenzyl>-2-methoxyberbin-3,10,11-triol|O4-Me-8-(4-Hydroxybenzyl)-2-methoxy-3,10,11-berbintriol
Ala Ala Ser Trp
Ala Ala Trp Ser
Ala Cys Ile Gln
Ala Cys Leu Gln
Ala Cys Gln Ile
Ala Cys Gln Leu
Ala Gly Thr Trp
Ala Gly Trp Thr
Ala Ile Cys Gln
Ala Ile Gln Cys
Ala Leu Cys Gln
Ala Leu Gln Cys
Ala Met Asn Val
Ala Met Val Asn
Ala Asn Met Val
Ala Asn Val Met
Ala Gln Cys Ile
Ala Gln Cys Leu
Ala Gln Ile Cys
Ala Gln Leu Cys
Ala Ser Ala Trp
Ala Ser Trp Ala
Ala Thr Gly Trp
Ala Thr Trp Gly
Ala Val Met Asn
Ala Val Asn Met
Ala Trp Ala Ser
Ala Trp Gly Thr
Ala Trp Ser Ala
Ala Trp Thr Gly
Cys Ala Ile Gln
Cys Ala Leu Gln
Cys Ala Gln Ile
Cys Ala Gln Leu
Cys Ile Ala Gln
Cys Ile Gln Ala
Cys Lys Pro Ser
Cys Lys Ser Pro
Cys Leu Ala Gln
Cys Leu Gln Ala
Cys Asn Val Val
Cys Pro Lys Ser
Cys Pro Ser Lys
Cys Gln Ala Ile
Cys Gln Ala Leu
Cys Gln Ile Ala
Cys Gln Leu Ala
Cys Ser Lys Pro
Cys Ser Pro Lys
Cys Val Asn Val
Cys Val Val Asn
Asp Gly Arg Ser
Asp Gly Ser Arg
Asp Arg Gly Ser
Asp Arg Ser Gly
Asp Ser Gly Arg
Asp Ser Arg Gly
Phe Gly Asn Pro
Phe Gly Pro Asn
Phe Asn Gly Pro
Phe Asn Pro Gly
Phe Pro Gly Asn
Phe Pro Asn Gly
Gly Ala Thr Trp
Gly Ala Trp Thr
Gly Asp Arg Ser
Gly Asp Ser Arg
Gly Phe Asn Pro
Gly Phe Pro Asn
Gly Ile Met Asn
Gly Ile Asn Met
Gly Leu Met Asn
Gly Leu Asn Met
Gly Met Ile Asn
Gly Met Leu Asn
Gly Met Asn Ile
Gly Met Asn Leu
Gly Met Gln Val
Gly Met Val Gln
Gly Asn Phe Pro
Gly Asn Ile Met
Gly Asn Leu Met
Gly Asn Met Ile
Gly Asn Met Leu
Gly Asn Pro Phe
Gly Pro Phe Asn
Gly Pro Asn Phe
Gly Gln Met Val
Gly Gln Val Met
Gly Arg Asp Ser
Gly Arg Ser Asp
Gly Ser Asp Arg
Gly Ser Arg Asp
Gly Thr Ala Trp
Gly Thr Trp Ala
Gly Val Met Gln
Gly Val Gln Met
Gly Trp Ala Thr
Gly Trp Thr Ala
Ile Ala Cys Gln
Ile Ala Gln Cys
Ile Cys Ala Gln
Ile Cys Gln Ala
Ile Gly Met Asn
Ile Gly Asn Met
Ile Met Gly Asn
Ile Met Asn Gly
Ile Asn Gly Met
Ile Asn Met Gly
Ile Gln Ala Cys
Ile Gln Cys Ala
Lys Cys Pro Ser
Lys Cys Ser Pro
Lys Pro Cys Ser
Lys Pro Ser Cys
Lys Ser Cys Pro
Lys Ser Pro Cys
Leu Ala Cys Gln
Leu Ala Gln Cys
Leu Cys Ala Gln
Leu Cys Gln Ala
Leu Gly Met Asn
Leu Gly Asn Met
Leu Met Gly Asn
Leu Met Asn Gly
Leu Asn Gly Met
Leu Asn Met Gly
Leu Gln Ala Cys
Leu Gln Cys Ala
Met Ala Asn Val
Met Ala Val Asn
Met Gly Ile Asn
Met Gly Leu Asn
Met Gly Asn Ile
Met Gly Asn Leu
Met Gly Gln Val
Met Gly Val Gln
Met Ile Gly Asn
Met Ile Asn Gly
Met Leu Gly Asn
Met Leu Asn Gly
Met Asn Ala Val
Met Asn Gly Ile
Met Asn Gly Leu
Met Asn Ile Gly
Met Asn Leu Gly
Met Asn Val Ala
Met Gln Gly Val
Met Gln Val Gly
Met Val Ala Asn
Met Val Gly Gln
Met Val Asn Ala
Met Val Gln Gly
Asn Ala Met Val
Asn Ala Val Met
Asn Cys Val Val
Asn Phe Gly Pro
Asn Phe Pro Gly
Asn Gly Phe Pro
Asn Gly Ile Met
Asn Gly Leu Met
Asn Gly Met Ile
Asn Gly Met Leu
Asn Gly Pro Phe
Asn Ile Gly Met
Asn Ile Met Gly
Asn Leu Gly Met
Asn Leu Met Gly
Asn Met Ala Val
Asn Met Gly Ile
Asn Met Gly Leu
Asn Met Ile Gly
Asn Met Leu Gly
Asn Met Val Ala
Asn Pro Phe Gly
Asn Pro Gly Phe
Asn Val Ala Met
Asn Val Cys Val
Asn Val Met Ala
Asn Val Val Cys
Pro Cys Lys Ser
Pro Cys Ser Lys
Pro Phe Gly Asn
Pro Phe Asn Gly
Pro Gly Phe Asn
Pro Gly Asn Phe
Pro Lys Cys Ser
Pro Lys Ser Cys
Pro Asn Phe Gly
Pro Asn Gly Phe
Pro Ser Cys Lys
Pro Ser Lys Cys
Gln Ala Cys Ile
Gln Ala Cys Leu
Gln Ala Ile Cys
Gln Ala Leu Cys
Gln Cys Ala Ile
Gln Cys Ala Leu
Gln Cys Ile Ala
Gln Cys Leu Ala
Gln Gly Met Val
Gln Gly Val Met
Gln Ile Ala Cys
Gln Ile Cys Ala
Gln Leu Ala Cys
Gln Leu Cys Ala
Gln Met Gly Val
Gln Met Val Gly
Gln Val Gly Met
Gln Val Met Gly
Arg Asp Gly Ser
Arg Asp Ser Gly
Arg Gly Asp Ser
Arg Gly Ser Asp
Arg Ser Asp Gly
Arg Ser Gly Asp
Ser Ala Ala Trp
Ser Ala Trp Ala
Ser Cys Lys Pro
Ser Cys Pro Lys
Ser Asp Gly Arg
Ser Asp Arg Gly
Ser Gly Asp Arg
Ser Gly Arg Asp
Ser Lys Cys Pro
Ser Lys Pro Cys
Ser Pro Cys Lys
Ser Pro Lys Cys
Ser Arg Asp Gly
Ser Arg Gly Asp
Ser Trp Ala Ala
Thr Ala Gly Trp
Thr Ala Trp Gly
Thr Gly Ala Trp
Thr Gly Trp Ala
Thr Trp Ala Gly
Thr Trp Gly Ala
Val Ala Met Asn
Val Ala Asn Met
Val Cys Asn Val
Val Cys Val Asn
Val Gly Met Gln
Val Gly Gln Met
Val Met Ala Asn
Val Met Gly Gln
Val Met Asn Ala
Val Met Gln Gly
Val Asn Ala Met
Val Asn Cys Val
Val Asn Met Ala
Val Asn Val Cys
Val Gln Gly Met
Val Gln Met Gly
Val Val Cys Asn
Val Val Asn Cys
Trp Ala Ala Ser
Trp Ala Gly Thr
Trp Ala Ser Ala
Trp Ala Thr Gly
Trp Gly Ala Thr
Trp Gly Thr Ala
Trp Ser Ala Ala
Trp Thr Ala Gly
Trp Thr Gly Ala
Arg-Gly-Asp-Ser
Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.
Belotecan
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01C - Plant alkaloids and other natural products > L01CE - Topoisomerase 1 (top1) inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059004 - Topoisomerase I Inhibitors C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor D004791 - Enzyme Inhibitors
(5aS,10bR)-2-(2,6-Diethylphenyl)-5a,10b-dihydro-4H,6Hindeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinium Tetrafluoroborate,99e.e.
(5aR,10bS)-2-(2,6-Diethylphenyl)-5a,10b-dihydro-4H,6Hindeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinium Tetrafluoroborate
Drotaverine hydrochloride
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
(2R)-N-Hydroxy-2-[(3S)-3-methyl-3-{4-[(2-methylquinolin-4-YL)methoxy]phenyl}-2-oxopyrrolidin-1-YL]propanamide
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
Brexpiprazole
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine D2L receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α1B (Ki=0.17 nM) and α2C receptors (Ki=0.59 nM)[1][2].